Hims & Hers Health (NYSE:HIMS) Announces Quarterly Earnings Results

Key Points

• Hims & Hers reported quarterly EPS of $0.03, missing analysts’ $0.06 estimate; revenue of $890.37 million also fell slightly short of the $892.88 million consensus.
• Shares fell 11.9% during Monday trading, reaching $22.90.
• Analysts’ consensus rating is Hold, with an average price target of $32.43; insiders sold 133,905 shares worth about $3.83 million over the past quarter.

Hims & Hers Health (NYSE:HIMS - Get Free Report) announced its earnings results on Monday. The company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.06 by ($0.03), FiscalAI reports. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The firm had revenue of $890.37 million for the quarter, compared to analyst estimates of $892.88 million.

Hims & Hers Health Stock Down 11.9%

Shares of HIMS traded down $3.10 during midday trading on Monday, reaching $22.90. The stock had a trading volume of 41,031,904 shares, compared to its average volume of 22,156,463. Hims & Hers Health has a 1-year low of $13.74 and a 1-year high of $42.70. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87. The company has a market cap of $5.34 billion, a price-to-earnings ratio of -36.34 and a beta of 2.53. The company's fifty day simple moving average is $28.43 and its two-hundred day simple moving average is $26.94.

Insiders Place Their Bets

In related news, insider Soleil Boughton sold 3,462 shares of the stock in a transaction on Wednesday, October 28th. The shares were sold at an average price of $27.60, for a total value of $95,551.20. Following the transaction, the insider directly owned 293,886 shares of the company's stock, valued at $8,111,253.60. This trade represents a 1.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 2,000 shares of Hims & Hers Health stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $29.70, for a total transaction of $59,400.00. Following the sale, the chief financial officer owned 234,527 shares in the company, valued at $6,965,451.90. This represents a 0.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 133,905 shares of company stock valued at $3,826,977. 11.76% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have recently issued reports on HIMS. Wall Street Zen raised Hims & Hers Health from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th. Citigroup cut their price target on Hims & Hers Health from $35.00 to $33.00 and set a "neutral" rating for the company in a report on Tuesday, August 11th. TD Cowen boosted their price objective on Hims & Hers Health from $25.00 to $30.00 and gave the stock a "hold" rating in a research note on Tuesday, August 11th. Barclays dropped their target price on Hims & Hers Health from $39.00 to $35.00 and set an "overweight" rating for the company in a report on Friday, August 21st. Finally, Deutsche Bank Aktiengesellschaft raised their price objective on shares of Hims & Hers Health from $25.00 to $26.00 and gave the stock a "hold" rating in a research report on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health has an average rating of "Hold" and a consensus price target of $32.43.

About Hims & Hers Health

Hims & Hers Health, Inc operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products.

The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.

Founded in 2017, the company initially launched its Hims brand and later introduced Hers, expanding its services to a broader audience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.